Locations:

Blood Cancers

Acute lymphoblastic leukemia ALL-L2 blood smear under light microscopy

February 1, 2022/Cancer/Blood Cancers

New Drug Combination Can Extend the Lives of Older Patients with Ph+ Acute Lymphoblastic Leukemia

Novel regimen may help overcome the shortcomings of traditional chemotherapy in geriatric population

Human liver tissue with Amyloidosis under a microscope.

January 25, 2022/Cancer/Blood Cancers

Addition of CAEL-101 to Anti-Plasma Cell Dyscrasia Therapy May Have Long-Term Benefits in Patients with AL Amyloidosis

Follow-up study confirms safety and tolerability of new treatment protocol

Photomicrograph of Acute Myeloblastic Leukemia (AML), a cancer of white blood cell

December 28, 2021/Cancer/Blood Cancers

Uproleselan May Improve Remission, Reduce Side Effects in Patients with Acute Myeloid Leukemia

Study finds drug safe and effective when combined with chemotherapy

December 23, 2021/Cancer/Blood Cancers

Novel Program Optimizes Diagnostic and Treatment Strategies for Rare Diseases

Multidisciplinary team tackles the management of 84 uncommon cancers and blood disorders

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Chimeric antigen receptor (CAR) therapy,

December 14, 2021/Cancer/Blood Cancers

Biomarkers Predict Outcomes of CAR T-Cell Therapy in Patients with Diffuse Large B-Cell Lymphoma

Treatment may be a lifesaving option for patients with relapsed or refractory disease

October 7, 2021/Cancer/Blood Cancers

Less-Intensive Therapies for Acute Myeloid Leukemia Tied to Higher Mortality Risks

Study reports on 11-year experience in AML

April 1, 2021/Cancer/Blood Cancers

CAR T-Cell Therapy Shows Promise in Treating Relapsed/Refractory Multiple Myeloma

Preliminary trial reports positive patient response

March 8, 2021/Basic & Translational Science

Molecular and Genetic Mechanisms in Bone Marrow Failure Syndromes and Myeloid Neoplasia

Results of two studies presented at the 2020 ASH Annual Meeting

February 24, 2021/Cancer/Blood Cancers

Azacitidine Shows Potential as a Treatment for Multiple Myeloma

Trial results point the way to further investigation

January 20, 2021/Basic & Translational Science

Selective Targeting May Have Therapeutic Potential in TET2-Mutant Neoplasia

TETi76 eliminates TET2-mutant and TET-deficient cancer cells

BackPage 3 of 7Next